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To perform a systematic review examining the variation in methods, results, reporting and
risk of bias in electronic health record (EHR)-based studies evaluating management of a
common musculoskeletal disease, gout.
Methods
Two reviewers systematically searched MEDLINE, Scopus, Web of Science, CINAHL,
PubMed, EMBASE and Google Scholar for all EHR-based studies published by February
2019 investigating gout pharmacological treatment. Information was extracted on study
design, eligibility criteria, definitions, medication usage, effectiveness and safety data, com-
prehensiveness of reporting (RECORD), and Cochrane risk of bias (registered PROSPERO
CRD42017065195).
Results
We screened 5,603 titles/abstracts, 613 full-texts and selected 75 studies including 1.9M
gout patients. Gout diagnosis was defined in 26 ways across the studies, most commonly
using a single diagnostic code (n = 31, 41.3%). 48.4% did not specify a disease-free period
before ‘incident’ diagnosis. Medication use was suboptimal and varied with disease defini-
tion while results regarding effectiveness and safety were broadly similar across studies
despite variability in inclusion criteria. Comprehensiveness of reporting was variable, rang-
ing from 73% (55/75) appropriately discussing the limitations of EHR data use, to 5% (4/75)
reporting on key data cleaning steps. Risk of bias was generally low.
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Conclusion
The wide variation in case definitions and medication-related analysis among EHR-based
studies has implications for reported medication use. This is amplified by variable reporting
comprehensiveness and the limited consideration of EHR-relevant biases (e.g. data ade-
quacy) in study assessment tools. We recommend accounting for these biases and per-
forming a sensitivity analysis on case definitions, and suggest changes to assessment tools
to foster this.
Introduction
A growing number of health organizations routinely use electronic health record (EHR) sys-
tems for patient management [1]. Many systems include electronic prescribing and these rec-
ords enable evaluation of patient management and exploration of issues such as guideline-
indicated treatment and medication adherence. This is informative for diseases that are pri-
marily managed with pharmacological interventions.
Musculoskeletal diseases are common in our ageing and increasingly obese populations.
Gout is the most common inflammatory musculoskeletal disease, with prevalence estimates
ranging between 0.1 and 10% worldwide [2]. It results from monosodium urate (MSU) crystal
deposition in articular and peri-articular tissues that leads to debilitating flares and joint dam-
age [3]. The management of gout involves medication usage for both acute and chronic cases
[3–5].
The growing coverage of EHRs, including electronic prescribing, has led to increasing
numbers of studies being conducted using this type of data to assess the burden and manage-
ment of chronic diseases in real-world settings. EHRs have been used in gout research to
examine temporal and demographic variations in treatment, quality of management and
patient outcomes [6–9]. However, EHRs are primarily designed to facilitate continuity and
billing in healthcare provision. Secondary use for research requires understanding of how
EHRs are used in clinical practice in order to design studies appropriately (e.g. clinicians may
use different codes to record an event depending on their training, experience and the design
of the EHR system). EHR-based studies use a variety of approaches to define and validate
events or cases, ascertain medication use and outcomes, and report methods and findings. An
understanding of the main factors that determine heterogeneity in estimates is essential for
interpreting study findings. Variation in approaches to EHR-based research and the impact
that method selection might have on results, as well as variation in comprehensiveness of
reporting and study quality of those studies, have not previously been assessed.
We therefore aimed to systematically review methods, results, reporting and risk of bias in
EHR-based studies evaluating pharmacological management. Gout, being a common rheuma-
tologic condition with predominant pharmacological management, and the focus of several
published EHR-based studies, was selected as an exemplar for this evaluation.
Materials and methods
Search strategy and study selection
We registered the study protocol in the International Prospective Register of Systematic
Reviews (PROSPERO), number CRD42017065195 [10]. The systematic review was conducted
in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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(PRISMA) statement (S1 Table) and the recommendations of Denison et al. [11, 12]. We
searched Scopus, Web of Science, CINAHL, PubMed, MEDLINE, EMBASE and Google
Scholar on 20 February 2019 for papers published since 1 January 1970 (Supplementary Meth-
ods in S1 File). The search strategy combined search terms for ‘electronic health records’,
‘gout’ and ‘medication’ with their synonyms (S2 Table). Two reviewers (SSRC and LLYH)
hand-searched relevant reviews, conferences, meeting and protocol publications and screened
titles and abstracts using Rayyan [13]. Full texts were then screened to select all EHR popula-
tion-based studies of gout, reporting on treatment utilization, effectiveness or safety (selection
criteria listed in Supplementary Methods in S1 File). A third reviewer (MP-R or SK) resolved
discrepancies.
Data extraction and quality assessment
A data extraction form was developed using Microsoft Access 2013, based on the recommen-
dations of the Centre for Reviews and Dissemination for general information, study and
participant characteristics, setting and results [14]. Characteristics such as ‘recruitment proce-
dures, costs and resource use’ were adapted to EHR-relevant details. Clinical and epidemiolog-
ical guidance from PC, PB and MP-R informed the data elements extracted. We classified the
approach taken to identify gout diagnoses as “liberal” if there was a risk of over-classifying
(high sensitivity) and “specific” if there was risk of under-classifying. Liberal approaches
required a single diagnostic code, free-text keyword or prescription unless it was recorded by a
rheumatologist. Specific approaches used further requirements concerning specialist care set-
ting, having further diagnostic codes or prescriptions, having tests or meeting guideline diag-
nostic criteria such as the 2015 American College of Rheumatology (ACR) / European League
Against Rheumatism criteria [15]. Two investigators (SSRC and LLYH) independently
abstracted the data and reviewer discrepancies were resolved by consensus with a third
reviewer (MP-R).
Comprehensiveness of reporting (CoR) of EHR data use was assessed using the REporting
of studies Conducted using Observational Routinely-collected Data (RECORD) statement
[16]. Study quality was assessed using the Cochrane Tool to Assess Risk of Bias (RoB) in
Cohort Studies [17]. CoR and RoB scores were calculated applying the Care Quality Commis-
sion Survey Scoring Method; answers ranked from 0–10 for the least to most positive answer
option [18]. The sum of answers per study was divided by the number of questions evaluated
to obtain an overall score for each study: ‘perfect’ scores were 10/10 CoR and 15/15 RoB.
Where a question was ‘not applicable’, it was excluded and did not affect the score [19].
Study outcomes
The outcomes were: indicators of gout diagnosis; medication types considered; methods/
results relating to treatment utilization (including their period of assessment in relation to the
timing of gout diagnosis); effectiveness and safety and association between these results and
the gout definition used (liberal or specific); CoR on EHR data use and RoB indicators, includ-
ing analyses of time-trend and according to gout definition and study size.
Statistical analysis
We performed descriptive statistics, using Microsoft SQL 2014 and Excel 2013, to describe def-
initions of gout, methods used, treatment utilization, effectiveness and safety, reporting quality
and RoB. To account for study sample size, weighted proportions and means/medians were
calculated for overall estimates of medication use and treatment outcomes. Change in scores
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based on cohort size and following the publication of CoR guidelines were assessed using Chi-
square tests for a linear trend.
Results
Study and cohort characteristics
Titles/abstracts for 5,603 articles were screened, 613 full-text articles were reviewed and 75
met the eligibility criteria (Fig 1, S3 Table). All studies were published between 2002 and 2019,
with a rising publication rate (R2 = 0.86) (S1 Fig). Most were conducted in the UK (n = 26)
(Table 1). Amongst 67 studies that reported the calendar period covered, the median duration
was 8 years (interquartile range (IQR) 3.5–15) and 52 (77.6%) used data recorded since 2010.
Fifty (66.7%) analysed data from primary care. Thirty-eight studies (50.7%) reported the num-
ber of sites considered and 19 (50.0%) of them were single-center (range 1–15 520). Only 31
(41.3%) reported the population size from which the cohort was drawn (range 8686–35
million).
Besides inclusion criteria regarding gout diagnosis or medication, some studies used further
criteria regarding: comorbidity (n = 17, 22.7%), age (n = 38, 50.7%), minimum period of
enrollment before follow-up start (n = 22, 29.3%), minimum follow-up duration (n = 14,
18.7%), minimum number of visits during the study or current registration status (n = 13,
Fig 1. Flow chart of study identification and selection. CINAHL, Cumulative Index of Nursing and Allied Health
Literature; EHR, electronic health record. � Studies including asymptomatic hyperuriceamia. ^Studies using databases
that are restricted to specific (non-gout) sub-populations (e.g. an adverse event database).
https://doi.org/10.1371/journal.pone.0224272.g001
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17.3%). Six studies (8.0%) excluded patients with missing demographic, prescription or labora-
tory values and 8 (10.7%) only included sites that met data entry quality standards. While 68
(90.7%) selected all eligible patients, 4 (5.3%) selected a random sample, and 3 (4.0%) consent-
ing patients. Gout cohort sizes increased over time (median 4368 patients, IQR 435–30 767).
Fifty-nine (78.7%) reported the sex distribution, 50 (66.7%) the mean/median age and 11
(14.7%) socio-economic status. Twenty-five (31.9%) reported mean/median follow-up dura-
tion, which was over 5 years for 12 studies.
Gout definition
Of 66 (88.0%) studies specifying the gout definition, 38 applied a liberal and 28 a specific
approach; 58 (87.9%) used diagnostic codes, 13 (19.7%) medication, 6 (9.1%) test results and 3
(4.7%) free text (Tables 2 and 3). Diagnostic coding was optional in 8 studies and required by
50 (of which 12 also required additional criteria). When using diagnostic codes, 51 (87.9%) ref-
erenced the coding system and 25 (43.1%) provided the code-list. None provided the medica-
tion code-list (7/75 (9.3%) provided these for medication variables). Three (23.1%) studies had
the applicable window of medication exposure before the study period, 5 (38.5%) during, 1
(7.7%) before or during [20], 1 (7.7%) current [21] and 3 (23.1%) did not specify it. Eleven
(14.7%) repeated their analyses using different gout definitions (sensitivity analysis). Thirty-
one (41.3%) defined incident gout: 29 (93.5%) by the first coded appearance and 16 (51.6%)
required a prior 1–5 years with no diagnosis or medication.
Table 1. Characteristics of studies included (n = 75).
Characteristic n (%) Characteristic n (%)
Geographic Setting� Site Type
Western Europe 41 Primary care 29 (39)
North America 25 Primary care and hospital 21 (28)
Asia 8 Hospital 13 (17)
Australia / New Zealand 4 Outpatient 4 (5)
Middle East 1 National dataset 7 (9)
Not specified 2 Nursing Facility 1 (1)
Study Design Year of Publication
Site-randomized trial (usual care cohort) 1 (1) 2000–2004 1 (1)
Matched cohort 6 (8) 2005–2009 6 (9)
Cohort 46 (61) 2010–2014 24 (35)
Case Control 16 (21) 2015–February 2019 44 (64)
Cross-sectional 6 (8) Gout Cohort Size
Study Aim �100 7 (9)
Epidemiology of gout 22 (29) 101–1,000 21 (28)
Patient management 6 (8) 1,001–10,000 15 (20)
Adherence to clinical guidelines 12 (16) 10,001–100,000 22 (29)
Adherence and gaps in therapy 5 (7) >100,000 7 (9)
Treatment safety 10 (13) Not specified 3 (4)
Treatment effectiveness 3 (4)
Patient knowledge, beliefs & education 1 (1)
Epidemiology; patient management 7 (9)
Other combination 9 (12)
�Some studies had multiple applicable settings.
https://doi.org/10.1371/journal.pone.0224272.t001
Variation in EHR-based studies of gout
PLOS ONE | https://doi.org/10.1371/journal.pone.0224272 October 24, 2019 5 / 18
Table 2. Definitions of gout and medication exposure (n = 75).
Definitions n (%)�
Gout Definition
�1 diagnosis 31 (45)
�1 EHR reference (not specified) 2 (3)
�1 gout medication prescription/dispense 2 (3)
�1 diagnosis or gout medication 2 (3)
�1 diagnosis or keyword 2 (3)
�1 keyword search of EHR 1 (1)
�1 diagnosis; 1 diagnosis and medication (2 definitions) 4 (5)
1 liberal and�1 specific definition (other than above) 4 (5)
�2 diagnoses 3 (4)
Survey response and�1 diagnosis 2 (3)
�1 diagnosis or medication and coded CKD, urolithiasis, tophus or >2 flares 2 (3)
� 1 test 2 (3)
Meet ACR criteria 3 (3)
Other specific definition/s (not seen in >1 study) 9 (12)
No definition given 6 (8)
Incident Gout Definition 33 (44)
First code in the study or EHR (% of 33) 31 (94)
No diagnosis in prior time period (1–3 y) (% of 33) 13 (39)
Distinct codes for incident and prevalent (% of 33) 1 (3)
No diagnosis and/or medication in prior time period (% of 33) 5 (15)
No definition given (% of 33) 2 (6)
Medication Minimum Duration/Dose Requirement 8 (11)
Minimum of 6 months 4 (5)
Minimum of 3 consecutive months 1 (1)
Minimum of 1 month 1 (1)
Minimum of 2 prescriptions 1 (1)
�300mg/day of allopurinol 1 (1)
Medication Exposure Measure
Binary ‘ever exposed’ at any point in the study 23 (31)
Binary ‘ever exposed’ at a specific time point 14 (19)
Binary ‘ever exposed’ in a specific time window 9 (12)
Exposure within a window 26 (35)
Continuous exposure 4 (5)
Cumulative exposure 3 (4)
Reporting on Medication Exposure
Use at baseline or prior to study 35 (47)
Dosage 33 (44)
% ‘ever exposed’ during the study 29 (39)
Use at or during follow-up periods 19 (25)
Temporal duration of medication use 9 (12)
Use in chronological periods 8 (11)
CKD, chronic kidney disease.
�Percentage is given as n out of 75 unless otherwise specified.
https://doi.org/10.1371/journal.pone.0224272.t002
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Medication assessment
Forty-five (60.0%) studies used prescriptions, 20 (26.7%) dispensary data and 3 (4.0%) both
(S1 Chart). Allopurinol, non-steroidal anti-inflammatories (NSAIDs) and colchicine were the
most common of 27 gout-related drugs or groups reported (S4 Table). Eight studies specified a
minimum prescription duration or dose.
Measures of medication use
Most studies reported the percentage with medication ‘ever used’ (n = 44, 59%, of which 26
only reported this) or use within specified windows (n = 26, 34.7%). Seven (9.3%) reported
continuous or cumulative exposure, 8 (10.7%) temporal prescribing trends and 32 (42.7%) the
prescribed dosage. Sixteen (21.3%) assessed the proportion initiating treatment at diagnosis or
in periods of follow-up, 2 prescription gaps and 1 the percentage with�60 consecutive days of
prescribing. Urate-lowering therapy (ULT) adherence was measured as a medication posses-
sion ratio (MPR) or the proportion of days covered (PDC)�0.80 in 1 and 8 (10.7%) studies
respectively.
Table 3. Distribution of studies according to elements considered in the definition of gout and medication expo-
sure and their classification recording system (n = 75).
Indicator Count (%)
Gout Diagnosis
Diagnostic Code 58 (88)
With provision of code-list (% of 58) 25 (43)
ICD (% of 58) 33 (57)
Read Code / Oxmis (% of 58) 18 (31)
Classification not specified (% of 58) 7 (12)
Medication 13 (20)
With provision of code-list (% of 13) 0 (0)
Multilex (% of 13) 5 (39)
BNF (% of 13) 1 (8)
Classification not specified (% of 13) 7 (54)
Test Result� 6 (9)
UA crystals in synovial fluid 4
Radiologic evidence, e.g. DECT scan 2
Biopsy of tophus or synovial tissue 1
High SUA level 2





National ID 2 (3)
BNF 1 (1)
Classification not specified 58 (77)
ATC, Anatomical Therapeutic Chemical; BNF, British National Formulary; DECT, dual-energy computed
tomography; ICD, International Classification of Diseases; SUA, serum uric acid; UA, uric acid
�Some studies used multiple tests in defining gout.
https://doi.org/10.1371/journal.pone.0224272.t003
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Reported estimates of medication use
Medication initiation was low although higher in studies with stricter definitions, with little
temporal change (S1 Chart). Studies selecting incident patients with�1 gout diagnosis (i.e.�1
diagnostic code) reported 6.7% (range 0–9.4%) of patients initiating ULT at diagnosis and
22.9% (range 16.9–25.4%) by 12 months [22, 23]. In studies also requiring prior registration
without diagnosis, this was 15% at diagnosis and 27.7% (range 23–31.9%) by 12 months [24–
28]. Kapetanovic et al. reported 47.8% and 60.6% of patients with incident gout receiving ULT
in 2011 when using a liberal and specific definition respectively [29]. Studies using a liberal
definition found stable ULT prescribing (mean 28.3%), declining NSAID use (mean 36.3%)
and rising colchicine use (mean 6.3%) across 1990 to 2014 among patients with incident and
prevalent gout [24, 25, 27, 30–32]. Arromdee et al. used a specific definition and reported
higher colchicine use: 19.8% in 1995–1996 [33].
ULT duration was short although longer in studies with a specific gout definition. It ranged
from 0.33–0.8 years in studies requiring�1 diagnosis (liberal) and 2.5–4.0 years in studies
including patients with�2 diagnoses [23, 34–37]. Scheepers et al. reported mean PDC of 0.57
(standard deviation (SD) ±0.34) for patients with�1 diagnosis, while Coburn et al. selected
patients with�2 diagnoses and reported median PDC 0.7 to 0.83 [23, 38]. The proportion
with PDC�80 in the first year was 38.6% among patients with�1 diagnosis [27, 39] and 59%
among patients with�1 diagnosis validated through a survey [40]. MPR was only measured
using a liberal definition [41].
ULT doses were low with limited up-titration although greater in studies with a specific
gout definition. The mean proportion of patients with ULT up-titration was 5.4% (range
4–36%) and 29.0% (range 22.4–39.3%) when using liberal and specific definitions respectively
[35, 37, 41–44]. The mean initial allopurinol dose was 148.1 mg/day and overall dose was 223.3
mg/day: 194.1 mg/day and 231.4 mg/day in studies with liberal and specific definitions respec-
tively [21, 34, 42, 45–50]. Inappropriate allopurinol dosing for renal disease patients was high
(mean 24.8%, range 22–25.9%) and only reported in studies using liberal definitions [51, 52].
Measures of treatment outcomes
Nine (12.0%) studies measured changes in serum urate (SUA) level with ULT: 7 measured
mean change and 4 the percentage achieving SUA level goal. Eight (10.7%) examined the
impact of ULT on disease control or SUA level, with 5 assessing associations with the starting
dose, titration and drug adherence. Other measures evaluated were the percentage of patients
reaching the SUA goal or switching treatment, the mean SUA change per treatment group,
comparison of changes in repeated-measures and time to response. Fifteen (20%) evaluated
treatment safety, with 9 determining effect on the risk of fracture, joint replacement, mortality,
myopathy, chronic kidney disease, hepatoxicity and cardiovascular disease.
Reported estimates of treatment outcomes
Studies, especially those with specific gout definitions, reported higher SUA level goal attain-
ment with higher starting allopurinol dose, adherence and up-titration [35, 38–40, 47]. For
example, Mantarro et al. used a liberal definition and reported lower odds of hyperuriceamia
in the first 90–149 days for adherent patients (AOR, 0.40; 95%CI, 0.24–0.67) [39]. Rashid et al.,
with a specific definition, reported higher odds of goal attainment associating with higher
starting doses (AOR, 1.92; 95% CI, 1.86–2.22 for 100–300 mg compared with�100mg) and
adherence (AOR, 2.52; 95% CI 2.41–3.01) [35]. ULT had a positive dosage- and duration-
dependent effect on SUA level (7/7 studies), and combination therapy was more effective than
monotherapy (2/2 studies), regardless of gout definition [35, 38–40, 44, 46, 47, 49, 53].
Variation in EHR-based studies of gout
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Most studies reported that treatment was safe and well tolerated, with few switches, regard-
less of gout definition. For example, with a liberal definition, colchicine associated with lower
cardiovascular risk and mortality compared to no medication; and with a specific definition it
was unrelated to myopathy risk when prescribed with vs without statin [54–56]. Only the asso-
ciation between allopurinol and all-cause mortality was examined using varied definitions
(both used propensity-matched cohorts): Kuo et al. used�1 diagnosis and reported no
improvement compared with non-exposed gout patients (HR, 1.01; 95% CI, 0.92–1.09);
Coburn et al. used�2 diagnostic codes and noted no improvement with titration (HR, 1.08;
95% CI, 1.01–1.17) [38, 57]. Both were hindered in investigating dosage-dependent effects by
pervasive low dosage prescribing.
Comprehensiveness of reporting
The overall mean score for CoR of EHR data use was 5.2/10 (SD±1.5): 5.6/10 (SD±1.3), 5.3/10
(SD±1.4) and 3.0/10 (SD±0.9) for studies with a liberal, specific and no stated approach to
defining gout respectively (range 1.8–8.5). Those with a liberal definition reported less com-
prehensively on validation, database population and linkage methodology but more frequently
provided full code-lists and the patient count at each selection stage.
In the title/abstract, 66 (88.0%) mention (“yes”/“partly”) the data (although 11 only name
the database) while 15 (20.0%) reported the geographic region, 9 (12.0%) the study timeframe
and 32 (42.7%) both (Fig 2, S5 Table). In the methods, cohort selection was the most compre-
hensively recorded (“yes”/“partly” = 70, 93.3%), while only 7 (9.3%) provided the codes or
algorithms for all variables, 6 (8.0%) provided a data availability statement and 4 (5.3%) made
�2 references to data cleaning or preparation. Seventeen (22.7%) provided incorrect refer-
ences to a gout diagnosis validation study; 7 referenced a study by Meier et al. that used more
specific selection criteria [58], 5 referenced studies using a different coding system to that used
in the study and 3 referenced studies that validated a disease other than gout. Fifteen used data
from the Clinical Practice Research Datalink, which trains clinicians in data-entry [59], but
only 8 (53.3%) noted this.
Fig 2. Percentage of studies with comprehensive reporting on RECORD items (n = 75). RECORD, REporting of
studies Conducted using Observational Routinely-collected Data.
https://doi.org/10.1371/journal.pone.0224272.g002
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Overall CoR scores rose over time (S2 Fig) and were higher after 2015, when RECORD
guidelines were published (x2 = 5.7, p = 0.02). The median score was 5.0 (IQR = 3.6–5.9) for
40 papers published by 2015, and 5.8 (IQR = 5.0–6.5) from 2016 (n = 35). The proportion scor-
ing “yes” or “partly” was greater for all items from 2016 except 13.1, with a mean change of
+15.5% (SD ±16.1). This ranged from 0.4% decrease in studies describing the selection of
included persons, to 56.3% increase in those describing the linkage methodology. However,
from 2016, “yes” scores decreased for items 1.1, 6.1, 6.3, 19.1; notably 15.4% fewer mentioning
the data type in the abstract and 14.3% fewer discussing the limitations of secondary data use.
The proportion with “yes” scores remained�25% for 6/13 items (6.2–7.1, 12.2, 12.3, 22.1).
Risk of bias
The mean RoB score was 12.0/15 (SD±1.6, range 7.5–15) and, where items were applicable to a
study, >85% of studies were scored with low or probably low RoB for each item. All studies
scored “yes”, “probably yes” or “not applicable” for having exposed and non-exposed cohorts
drawn from the same population and confidence in the assessment of the presence or absence
of prognostic factors (Fig 3). In 8 (10.7%) studies patients were inappropriately matched or
estimates were incorrectly adjusted and 6 (8.0%) inadequately assessed the outcome at follow-
up start. However, the RoB measures were not applicable to, on average, 30.8% of studies per
item (IQR 10.0–34.7%). The similarity of co-interventions between groups compared, and
whether cohorts were drawn from the same population, were non-applicable for 74 (98.7%)
and 38 (50.7%) studies respectively.
Mean RoB scores were 12.0 (SD±1.3), 11.8 (SD±1.8) and 12.6 (SD±1.9) for studies with a
liberal, specific and unspecified gout definition. Overall RoB scores did not change over time
(x2 = 2.8, p = 0.09), (S3 Fig) and were similar amongst studies with<1000 and�1000 gout
patients (x2 = 0.38, p = 0.53) (S4 Fig).
Discussion
This is the first systematic literature review of variation in methods, results and reporting in
EHR-based studies of gout medication. The studies demonstrated wide variation in definitions
and medication-related methods. This did not widely affect effectiveness and safety estimates,
Fig 3. Percentage of studies with low risk of bias as assessed with the Cochrane Tool for Cohort Studies (n = 75).
https://doi.org/10.1371/journal.pone.0224272.g003
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though reporting quality was variable. Risk of bias was acceptable as assessed by the Cochrane
tool although its applicability to EHR-based studies was limited.
Gout definition
Variation in gout definition and medication-related methods may explain differences in medi-
cation utilization estimates across the studies. Most studies employed liberal approaches that
may lead to more misdiagnosis (false positives) when suspected cases are recorded in EHRs
during pre-diagnostic evaluation. Specific approaches are likely to have higher specificity but
may lack sensitivity for identifying mild or recently diagnosed cases (i.e. severe or long-stand-
ing cases benefit from additional clinical contact, increasing opportunities for prescribing,
tests and diagnostic coding). We recommend that EHR-based studies replicate key analyses
using a liberal and specific definition (sensitivity analysis) and discuss potential implications of
any discrepancies. We also advise that diagnostic definitions adopt contemporary guideline
diagnostic criteria as far as possible and describe any constraints encountered in doing so.
Medication assessment
No studies considered time since diagnosis, and assessment of severity or flare frequency is dif-
ficult in EHR data [36]. The medications studied were varied and little was reported regarding
cumulative dosage and timing in relation to clinical events such as testing. Most studies mea-
sured variables that are well recorded in EHRs: SUA level, medication, comorbidities and pro-
cedures. There were varied approaches to measuring adherence and we recommend the
practice of accounting for dose changes and early fills to avoid over-estimation.
Medication use and treatment outcomes
EHR-based research has used prescription data to reflect the real-world challenges faced by cli-
nicians in management of gout. ULT initiation, adherence and titration was sub-optimal and
doses rarely reached above 300 mg/day. The studies in this review used EHR data from 1977 to
2017 with comprehensive coverage of prescriptions and consistently found a lack of improve-
ment in gout pharmacological management over time. This is problematic given the disassoci-
ation from guideline recommendations and trial evidence showing that doses�300 mg/day
fail to reduce SUA levels [4]. Estimates of medication use were higher and less heterogeneous
in studies using specific gout definitions. These studies may select more severe and long-stand-
ing cases, so gout management may be slightly more appropriate in these instances. If prescrib-
ing improves, EHR-based research could evaluate prescribing patterns, dosage-dependent
safety and effectiveness, and safety of concomitant prescribing. ULT was generally reported as
safe and effective regardless of definition or methodology, which indicates the opportunity for
optimizing gout control though ULT.
Comprehensiveness of reporting
There is significant scope for improving reporting of EHR-based research to facilitate repro-
ducibility and understanding of bias and representativeness. For example through reporting of
the timeframe and data linkages in the abstract; sharing code-lists (e.g. in supplemental mate-
rial or publically available repositories); adequately describing definitions, validation and link-
age; and reporting the cohort size during each selection stage.
We found reporting differences between studies using liberal and specific gout definitions
in CoR. The former more commonly provided code-lists for definitions and the cohort count
at each selection stage. The latter reported more on validation, database population and
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linkage, which may be explained by a greater understanding of how healthcare provision
determines data collection and use of this to develop a more systematic approach to cohort
design and study definitions.
Publication of RECORD guidelines in 2015 may account for the observed improvements in
CoR though no studies referenced RECORD. The recent shift from full to partial reporting of
the data type in the abstract and of discussion of implications of secondary data use may reflect
increasing familiarity of researchers with EHR-based research. Declines in reporting of the
cohort size during patient selection may reflect increasing use of centralized databases and
modalities of data sharing across EHR-based studies generally.
There were difficulties in assessing certain RECORD items, for reasons that will apply to all
EHR-based studies. For example, researchers rarely have full access to the EHR database popu-
lation and no studies reported this (RECORD item 12.1). We therefore scored instead by
whether studies described and appropriately referenced the database (profile, coverage or vali-
dation studies), which enables consideration of selection bias. The RECORD items are listed
by the area of the manuscript (e.g. abstract, methods) in which they should appear. For items
listed in the methods and results, we awarded a score if they were reported in either section.
RECORD item 6.3 considers a graphical display of the count of individuals in each linkage
stage; we adapted this to apply to all studies by considering display of individuals in each selec-
tion stage.
Risk of bias
RoB measures were generally low, especially in recent studies, but the Cochrane items assessed
were “non-applicable” in a third of instances (e.g. those related to co-interventions or estimate
adjustment) because many EHR-based studies, both in this review and in general, are
descriptive.
EHR-relevant biases
Other items not considered by commonly used assessment tools are pertinent to both con-
ducting and interpreting EHR-based research. Our systematic review highlights the impor-
tance of taking into account the impact of chosen definitions on the findings of research.
Other factors include adequacy of the dataset to answer the research question (e.g. hospital ver-
sus primary care for studying diabetes) and consideration of temporal changes including, diag-
nostic certainty, code classifications and completeness and accuracy of recording. Researchers
should consider changes in guidelines regarding diagnosis and management, payment prac-
tices or policymaking that affect clinical practice or EHR utilization, in study design, analysis
and interpretation. Data providers should publically detail all steps undertaken to create a
dataset, database profiles and results of data quality assessments. This would facilitate report-
ing, calibration and the capacity to relate findings back to EHRs for personalized interventions.
EHR linkage brings opportunity for multi-site research but may bring site-level bias if appro-
priate statistical methods (e.g. random-effects models) are not used, yet no multicenter study
in this review reported using such methods. This is not specifically covered by common RoB
tools for cohort studies.
We looked for discussion of unmeasured confounding, selection bias and changing eligibil-
ity over time when assessing reporting of the limitations of secondary data use (RECORD
19.1). These are not assessed by Cochrane but the former two are assessed by ROBINS-I and
Newcastle-Ottawa tools [17, 60, 61]. Acquisition bias, where events occurring outside the
study window (e.g. diagnoses or prescriptions) affect estimates, was not discussed by any study
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nor assessed by the tools. Unequal follow-up duration (data window length), competing risks
or loss-to-follow-up due to patient- or EHR system- migration can introduce bias but were not
specifically considered in the tools or all studies. Table 4 lists these EHR-related factors for
incorporation in future CoR and RoB tools.
Strengths and limitations
This review comprehensively evaluated all aspects of EHR data-use in gout management
research (methodology, use and outcomes, reporting and study quality) and the use of com-
mon tools for bias risk and reporting assessment. The limitations include restriction to publi-
cations in English and the lack of a standardized term for EHR-based research (e.g. studies
may only name a source database or allude to “records”). Due to the EHR focus of the review,
we adopted a previously published approach to exclude studies not referencing an EHR-based
source even though insurance, claims and administrative data could have been EHR-derived
[62].
Conclusions
EHR-based gout studies used varied case-definitions and medication-related methodology
which affects the ability to evaluate and compare treatment outcomes. Nevertheless, they con-
sistently reported that ULT is effective, safe and sub-optimally prescribed. Researchers should
improve reporting of methods for reproducibility, particularly through provision of code-lists,
data preparation steps and coding validation. Adapted CoR and RoB tools are also required for
evaluation of EHR-based research.
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